| Summary: | Probiotics developed for topical applications in humans have the potential to beneficially modulate microbial imbalances on the skin surface and thereby improve skin health. This study was conducted to determine whether topical formulations containing the human skin commensal <i>Micrococcus luteus</i> strain Q24 (BLIS Q24) are safe, tolerable and efficacious when used by healthy human subjects. <i>M. luteus</i> Q24 was assessed in vitro for haemolytic activity and its antibiotic susceptibility profile. Formulations of strain Q24 were evaluated for the preliminary safety and tolerability in healthy human participants. Forty-seven adults were randomly assigned to four single-site, single-blind randomised placebo or baseline controlled or active-controlled trials. Skin swab samples were collected for differential viable counts to monitor levels of probiotic colonisation. <i>M. luteus</i> Q24 was found to be non-haemolytic and susceptible to commonly used antibiotics. The <i>M. luteus</i> Q24 formulations were safe and tolerable and >90% of the participants reported improvements from baseline in the appearance (e.g., radiance and hydration) of their treated skin. Additionally, participants observed a reduction in pore size, skin clarity and enhanced skin softness. No adverse effects were reported. A dose-related significant increase was observed in the levels of <i>M. luteus</i> Q24 isolated from skin swabs of the probiotic-treated subjects. Placebo-controlled trials in human subjects involving the topical application of different doses of <i>M. luteus</i> Q24 formulations were supportive of the safety, tolerability and efficacy of probiotic <i>M. luteus</i> Q24. Self-reported skin health assessments by the subjects indicated that <i>M. luteus</i> Q24 has good potential as a probiotic for improving skin health quality.
|
|---|